Funding for the Cancer Research UK Manchester Institute

The total funding of the Cancer Research UK Manchester Institute for 2017 was £27m. The major source of this funding was awarded by Cancer Research UK via a core grant of £12.9m plus additional strategic funding of £5.5m. This funding enables the various scientific groups and service units within the Institute to carry out their research. 


The infrastructure of the CRUK Manchester Institute is funded by HEFCE generated income at a cost of £2.1m.

The balance of the Institute’s funding is received from a number of additional sources.  The research carried out through these additional projects enhances and supports the research undertaken by the core funding.

These sources are as follows:

  • Amgen
  • Angle Inc
  • Astex Pharmaceuticals
  • AstraZeneca
  • Bioven
  • Bloodwise
  • Carrick Therapeutics
  • CellCentric
  • Christie Hospital NHS Foundation Trust
  • Clearbridge Biomedicals
  • CRT Pioneer Fund
  • Euclises Pharmaceuticals Inc
  • European Commission
  • European Research Council
  • Fondation ARC pour la Recherche sur le Cancer
  • GlaxoSmithKline
  • John Swallow Fellowship
  • Kay Kendal Leukaemia Fund
  • Leo Pharma Foundation
  • Menarini Biomarkers Singapore
  • Merck
  • Moulton Charitable Trust
  • National Institute of Health Research
  •  Pancreatic Cancer Research Fund
  • Pickering Leukaemia Research
  • Prostate Cancer UK
  • Rosetrees Trust
  • Taiho Oncology Inc
  • The US Department of Health and Human Services
  • Wellcome Trust
  • Worldwide Cancer Research

We are immensely grateful to all our sponsors.